Regentis Biomaterials Ltd. (RGNT) is a publicly traded the market company. As of May 21, 2026, RGNT trades at $2.21 with a market cap of $10.00M and a P/E ratio of 0.00. RGNT moved +0.00% today. Year to date, RGNT is -67.10%; over the trailing twelve months it is flat. Its 52-week range spans $1.82 to $8.35. Analyst consensus is buy with an average price target of $10.00. Rallies surfaces RGNT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes RGNT SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $2.21 |
| Market Cap | $10.00M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $8.35 |
| 52-Week Low | $1.82 |
| Volume | 1.35K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
1 analysts cover RGNT: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $10.00.